Remdesivir shortens the amount of recovery time from COVID-19 and decreases the risk of death, final results of a study by the National Institutes of Health (NIH) show. Researchers found that the antiviral drug reduced the recovery time for hospitalized coronavirus patients by at least five days. Manufactured by California-based Gilead Sciences Inc, remdesivir is the only drug approved for emergency use in the US to treat severely ill coronavirus patients. For the final results, published in the New England Journal of Medicine, the NIAID recruited 1,062 coronavirus patients across North America, Europe and Asia. Patients in the remdesivir group recovered with a median of 10 days compared to 15 days for those who were given the placebo.

Source: Daily Mail October 08, 2020 21:01 UTC